Discover the Best Stocks and Maximize Your Portfolio:
- See what stocks are receiving strong buy ratings from top-rated analysts.
- Filter, analyze, and streamline your search for investment opportunities with TipRanks’ Stock Screener.
An update from Recce Pharmaceuticals Ltd. ( (AU:RCE) ) is now available.
Recce Pharmaceuticals Ltd has requested a trading halt on its securities pending the release of significant clinical trial data regarding its Phase II Acute Bacterial Skin and Skin Structure Infections (ABSSSI) clinical trial. This strategic move is anticipated to impact the company’s market positioning by potentially advancing its product portfolio in the anti-infective drug sector, which could have significant implications for stakeholders.
More about Recce Pharmaceuticals Ltd.
Recce Pharmaceuticals Ltd operates in the pharmaceutical industry, focusing on developing and commercializing anti-infective drugs. The company’s primary products aim to address bacterial infections, including those affecting the skin and skin structures.
YTD Price Performance: -9.38%
Average Trading Volume: 119,379
Technical Sentiment Consensus Rating: Strong Buy
Current Market Cap: A$102M
See more insights into RCE stock on TipRanks’ Stock Analysis page.
